Davita Inc vs LYFT Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while LYFT Inc trades at $16.16 (market cap $6.11B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and LYFT Inc for 47 Days on average.
| DVA | LYFT | |
|---|---|---|
Market Cap | $11.29B | $6.11B |
Volume | 582,204 | 13,504,560 |
Sector | Health | Technology |
52-Week High | $240.96 | $24.57 |
52-Week Low | $103.87 | $12.65 |
Typical Hold Time | 113 Days | 47 Days |
Enterprise Value | $24.01B | $5.57B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Lyft trades at $15.60, down 1.02% on the day, with a bullish technical outlook supported by moving averages despite recent earnings misses. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, while recent developments include European expansion and a $272.5M legal settlement. Cash flow has improved significantly, with operating cash flow reaching $1.17B in 2025.
Lyft presents a mixed investment case with attractive valuation metrics (P/E 2.35, P/S 0.96) but faces execution risks from recent earnings misses and competitive pressures. The 36.67% analyst buy rating and $18.07 consensus target suggest moderate upside potential, though regulatory concerns and market volatility remain key risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →